The markets are open and there is no time to waste this AM. Currently, I'm watching one profile that appears to be breakout ready based on


New Nasdaq Biopharma Profile (DARE) Could Be Breakout Ready Backed By Key Potential Catalysts

Major Analyst Price Targets Of $7.50 And $7.00 Paint The Picture Of A Currently Undervalued Stock

Brookeline Capital Markets + ROTH Capital Targets Found Here

October 19th

Good Morning,

The markets are open and there is no time to waste this AM.

Currently, I'm watching one profile that appears to be breakout ready based on several potential catalysts that I'll highlight below.

Before you do anything else, get this new Nasdaq biopharma idea on your radar:

Daré Bioscience, Inc. (DARE)

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women.

DYK: Key Statistics On The Contraceptive Market

The U.S. contraceptive market size is projected to reach $9.6Bn by 2027 expanding at a CAGR of approximately 4.2%.

37Mn U.S. women of reproductive age are estimated to currently use a contraceptive method.

Three Contraceptive Examples From Big Industry Players

#1. Mirena® Hormone IUD

Physician inserted, long-acting. low/locally delivered hormone IUS

2019 worldwide sales: €1.2Bn (Bayer)

#2. Lo Loestrin®

Lowest amount of daily estrogen (10 micrograms) available in pill form

2019 US sales: $588Mn (Allergan)

#3. NuvaRing®

Monthly vaginal ring

2019 worldwide sales: $879Mn (Merck)


These figures are important to follow closely because of DARE's licensing agreement with Bayer, the initial company listed above and all-around household name.

#1 Top Potential Catalyst For DARE

Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive

  • Daré may be entitled to up to $310Mn in commercial milestone payments plus tiered royalties on net sales in the double-digits
  • Daré is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health

WHIPPANY, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bayer, a leader in women’s health, and Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health, announced today that the companies have signed a license agreement under which Bayer may commercialize Daré’s investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.

Ovaprene is an investigational hormone-free monthly vaginal contraceptive currently in clinical development for the prevention of pregnancy. If approved, it could be the first monthly non-hormonal contraceptive product.

"We believe Bayer is best positioned to maximize the market opportunity for Ovaprene, which has the potential to be a first-in-category product for women, as Bayer has with other first-in-category products,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “This agreement provides Daré the opportunity to immediately benefit from Bayer’s expertise in development, regulatory, and commercialization, to unlock the program’s full value similar to other innovative contraceptive brands.”

Under the agreement, Daré will receive an upfront payment and access to Bayer’s extensive clinical and market capabilities while retaining control over Ovaprene’s development and regulatory approval process. Bayer receives the right to obtain exclusive rights to commercialize the product in the U.S. following completion of the pivotal clinical trial being undertaken by Daré. If Bayer, in its sole discretion, makes payment to Daré of $20Mn, which Daré intends to apply to reimbursement of clinical study costs, then the exclusive license to commercialize Ovaprene in the U.S. will become effective. Daré will also be entitled to receive commercial milestone payments potentially totaling $310Mn, in addition to double digit tiered royalties on net sales.

“Both Daré and Bayer share an intense passion of developing products and medicines that enhance the lives of women,” said Dr. Sebastian Guth, Bayer’s President of Pharmaceuticals, Americas Region. “Low or no hormones in contraceptives is something many women prefer, and we are proud to collaborate with a partner who shares a similar commitment to bringing products to market that can make a meaningful impact for women, their families and communities.”

Read the full article here.

Here's where DARE is currently in the Ovaprene process:


As 2022 fast approaches, the future of DARE couldn't look any brighter.

In fact, just take a look at the rest of DARE's potential products in the pipeline and how the next few years could lead to the company becoming a household name.



More Potential Catalysts: Two Major Analyst Price Targets

Back on April 28th, Brookline Capital Management analyst Sally Yanchus tagged DARE with a $7.50 price target.

Additionally, she provided a "BUY" rating.

Last month, Roth Capital analyst Zegbeh Jallah initiated coverage with a "BUY" rating and a price target of $7.00.

From Friday's close of $1.04, DARE is providing potential upside of 621% to the $7.50 target and potential upside of 573% to the $7.00 target.

Now, I'm not saying that DARE is going to go surging over 500% today, but the potential upside based on these analyst recommendations is massive.

Find the price targets here.

Two More Potential Catalysts - Recent News Hits The Wire

Daré Bioscience Receives $0.9Mn Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)

Contraceptive Program Supported by approximately $20.5Mn in Grant Funding from the Bill & Melinda Gates Foundation to Date

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9Mn in funding under the current grant from the Bill & Melinda Gates Foundation. The grant payment will support ongoing development activities for Daré’s investigational user-controlled, long-acting reversible contraceptive (UC-LARC), DARE-LARC1. Development of DARE-LARC1 has been supported by approximately $19.5Mn in grant funding from the foundation prior to this most recent disbursement.

The technology underpinning DARE-LARC1 is designed to store and precisely deliver therapeutic doses over months or years in a single implant and was originally developed at the Massachusetts Institute of Technology (MIT) by renowned researchers Robert Langer, Ph.D. and Michael J. Cima, Ph.D.

“We believe the non-dilutive funding support from the foundation for the development of DARE-LARC1 is a clear validation of the unmet need in the long-acting, reversible contraceptive, or LARC, category,” said Sabrina Martucci Johnson, President & CEO of Daré Bioscience. “LARCs are one of the most successful innovations in contraception, due to their exceedingly high effectiveness rates and duration of protection ranging from 3 to 10 years. The current FDA-approved LARCs require physician insertion and subsequent removal procedures for return to fertility, which can be a deterrent for women who know they will likely want to pause their contraception at some point during a typical 3 to 10 year implant duration. Our DARE-LARC1 program seeks to improve upon this product profile by providing a user-controlled LARC with a comparably high level of contraceptive effectiveness that will not require a woman to undergo procedures to remove and re-insert the device when she wants to return to fertility and, subsequently, when she wants resume contraception.”

DARE-LARC1 is a preclinical stage implantable contraceptive product that is designed to deliver the benefits of traditional long-acting, reversible contraceptive products with the added flexibility of wirelessly controlling the duration of drug release based on individual user needs. The implant is intended to be operated by the user to deliver medication on a pre-determined schedule that can be activated or deactivated wirelessly, as required to provide contraceptive protection or enable her to return to fertility. This grant payment will support critical ongoing preclinical activities necessary to advance the program to the next stage of development.


Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

Agreement Intended to Facilitate Advancement of Daré’s Programs in a Capital Efficient Manner; Includes Economic Structures and Opportunities for Dedicated Staff

SAN DIEGO and ANN ARBOR, Mich., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract research, development, and manufacturing organization specializing in chemical analysis and product development, today announced that the companies have signed an agreement under which Avomeen will provide contract product development laboratory services with a team specifically assembled to support the advancement of Daré’s innovative pipeline of investigational products designed to address persistent unmet needs in women’s health. The unique partnership model is intended to enable Daré to leverage Avomeen’s scientific expertise, including advanced instrumentation and development techniques, and accelerate development of key programs in a capital-efficient manner.

Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline. Central to the collaboration is Avomeen’s ability to develop customized protocols, test methods, and formulations with processes tailored to unique product requirements and specifications. This capability aligns with Daré’s portfolio of potential first-in-category products, which often require a customized approach to method development.

“One of the clear goals of this partnership is to leverage Avomeen’s ingenuity and expertise in biopharmaceutical development to support our clinical program initiatives in women’s health,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Avomeen has a proven track record and impressive regulatory accreditations combined with cutting-edge technological capabilities that we believe will enable us to accelerate development activities across our portfolio. Further, we believe that the partnership agreement will result in greater efficiencies and savings in our research and development expenditures.”

Under the terms of the agreement, Avomeen will be Daré’s preferred provider of product development laboratory services for an initial three-year period, provided that Avomeen has the expertise, resources and availability to perform the services that Daré requires. In exchange for receiving that exclusive service provider status, Avomeen will assemble operating and oversight teams committed to the partnership and provide a preferred discounted pricing structure and, if volume reaches designated levels, will also provide scientific personnel dedicated exclusively to supporting Daré’s development programs covered by the agreement.

“Avomeen is excited about this partnership and is well positioned to augment the existing clinical technical and regulatory competencies at Daré,” said Mark Harvill, CEO of Avomeen. “We have been able to apply our novel scientific and technical solutions to Daré’s diverse portfolio, in large part due to the collaborative approach that Daré implements with its development partners like Avomeen.”


Top 5 Potential Catalysts To Research On DARE

1. Signed License Agreement With Bayer

2. $7.50 Analyst Price Target From Brookeline Capital Management

3. $7.50 Analyst Price Target From ROTH Capital

4. Recent grant funding from the Bill & Melinda Gates Foundation

5. Forming A Strategic Partnership With Avomeen


Coverage is officially initiated on DARE immediately.


If there are any updates today, I'll get them out to you quickly.


Kai Parker



(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierce investor . com (“FI”), an interest in the limited liability company that owns and operates stock street wire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, Stock Wire News, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between Stock News Wire LLC and Complete Investment Management LLC, StockWireNews has been hired for a one day period beginning on 10/19/20 to publicly disseminate information about (DARE) via Website, Email and SMS. Stock News Wire LLC was paid thirty thousand USD via bank wire transfer. Stock Wire News owns zero shares of (DARE). A holder or two holders of DARE have paid Stock News Wire, LLC the sum of thirty thousand USD to publish favorable information about DARE. The holder or the two holders intend to sell their shares of DARE while we publish favorable information about DARE. Please see the full disclosure here: stock wire news . com.